Clinical trial · Observational
The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma
NCT06863441CI-TRIAL-00086909not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study on the value of PET imaging targeting granzyme B in predicting the efficacy and prognosis of T-NK cell lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| T-NK Cell Lymphoma | Nasal Type Extranodal NK/T-Cell Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- patients diagnosed with T-NK cell lymphoma who will receive immunotherapy
Primary outcomes (1)
- measure
- Standardized uptake value (SUV)
- timeFrame
- Baseline and 7-10 days after treatment
- description
- SUV of 68Ga-grazytracer uptake on PET/CT images for tumor lesions
Secondary outcomes (2)
- measure
- Progress free suivival
- timeFrame
- 3 years
- description
- Progress free suivival
- measure
- Overall survival
- timeFrame
- 3 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age \> 18 years, regardless of gender. 2. Histopathologically confirmed diagnosis of T-NK cell lymphoma. 3. Newly diagnosed and untreated patients or refractory/relapsed patients preparing to undergo immunotherapy. 4. Availability of complete clinicopathological and follow-up data. 5. Signed and dated informed consent form. Exclusion Criteria: 1. Patients who have previously received anti-tumor therapy. 2. Patients with a history of other malignancies. 3. Incomplete clinical information or imaging data. 4. Concurrent other malignant tumors. 5. Patients with severe medical conditions deemed unsuitable for participation in this clinical study by the investigator, such as severe cardiopulmonary insufficiency or severe hepatic and renal dysfunction. 6. Poor compliance.
References
Publications (0)
Data not yet available
No reference posted for this study.